Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
Original language | English (US) |
---|---|
Pages (from-to) | 2233-2235 |
Number of pages | 3 |
Journal | Neurology |
Volume | 67 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2006 |
ASJC Scopus subject areas
- Clinical Neurology